Stay updated with breaking news from Objective Response Rate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (anti-PD1 + ISA101b) - Deep and durable responses have a profound positive effect
/PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, today announces...
Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable Patients Remains on Track for the First Half of 2022 Data
Investegate announcements from NuCana plc, NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...